# HEP DART 2019: Frontiers in Drug Development for Hepatology

> **NIH NIH R13** · EMORY UNIVERSITY · 2020 · $8,500

## Abstract

Abstract/ Project summary:
HEP DART: Frontiers in Drug Development for Hepatology is an independent biennial conference
attracting at least 250 attendees for the past 24 years. HEP DART is open to anyone interested in
therapies for viral hepatitis and chronic liver disease. The content of this conference was developed to
interest primarily scientists and clinical researchers with a focus on drug development and
vaccinology. The aim of HEP DART 2019 is to assemble clinicians, researchers, basic scientists, nurses
and physician assistants together to advance our knowledge of the ongoing drug development
processes in the treatment of viral hepatitis (HBV, HCV, HDV, HAV and HEV), non‐‐‐alcoholic
steatohepatitis (NASH) and hepatocellular carcinoma (HCC). HEP DART will uniquely blend the
areas of biology, chemistry, pharmacology and clinical research to provide the scientific community
with an increased understanding of the current and future challenges in therapeutics for liver infection,
disease and cancer. OBJECTIVES: (1) Highlight advances in drug development against viral hepatitis
such as HBV, HCV, and HDV. (2) Describe the latest developments in HBV curative strategies. (3)
Highlight advances in drug development against NASH, fibrosis and HCC. (4) Describe novel
biomarkers for viral hepatitis, liver disease, and treatment outcomes. (5) Review current treatment and
vaccination guidelines for viral hepatitis; describe advancements in improved treatment regimens. (6)
Understand the consequences of HBV infection and NASH in pediatrics and adolescent populations. (7)
Assess the role of vaccines and therapeutic vaccines in future therapies for viral hepatitis, NASH, and
co‐‐‐infections with HIV. (8) Understand the epidemiology and pathogenesis of HDV, HAV and HEV.
METHODS: HEP DART 2019 comprises four days of scientific presentations, delivered in both oral
and poster presentations formats via non‐‐‐concurrent sessions. Emory University, Office of
Continuing Medical Education designates HEP DART for a maximum 24 category 1 credits toward the
AMA Physician’s Recognition Award. HEP DART provides a relaxed and scientifically stimulating
atmosphere for both PhDs and MDs to network and learn together. Support is requested to help defray
costs of scholarships and travel grants for young investigators, women, visible minorities and other
under‐‐‐represented delegates.

## Key facts

- **NIH application ID:** 9914390
- **Project number:** 1R13AI150088-01
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** Charles M Rice
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $8,500
- **Award type:** 1
- **Project period:** 2019-11-20 → 2020-10-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9914390

## Citation

> US National Institutes of Health, RePORTER application 9914390, HEP DART 2019: Frontiers in Drug Development for Hepatology (1R13AI150088-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/9914390. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*